Viral Conjunctivitis Drugs Market – Impact of Coronavirus (Covid-19) Pandemic –Size Is Anticipated To Reach US$ 293.7 Mn at a CAGR of 4.7% By 2027
Global Viral Conjunctivitis Drugs Market
Global Viral Conjunctivitis Drugs Market, by Drug Class (Antibiotics, Artificial tears, Steroids, NSAIDS, Anti-histamines, Anti-Viral drugs, and Decongestants), by Virus Type (Enterovirus and Adenovirus), by Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and by Region (North America, Asia Pacific, Latin America, Europe, Middle East, and Africa), is anticipated to attain a market valuation of US$ 293.7 million in 2021, and is poised to grow at a CAGR of 4.7 percent over the forecast period (2021-2028).
Due to the increasing number of product releases, North America is projected to retain a prominent position in the global viral conjunctivitis drugs market throughout the forecast period. Bausch & Lomb released Alaway Preservative Free antihistamine eye drops on February 23, 2021. It is used to treat conjunctivitis-related irritation in the eyes.
Market participants are engaging in aggressive operations such as company acquisitions, which is projected to propel the global viral conjunctivitis drugs market forward.
Impact of COVID-19 Pandemic
On December 31, 2019, a COVID-19 epidemic was first detected in Wuhan, China. According to the World Health Organization’s Coronavirus (COVID-19) Weekly Epidemiological Update, approximately 167 million cases and 3.4 million fatalities due to COVID-19 were recorded worldwide up until May 25, 2021.
The COVID-19 pandemic has impacted numerous markets throughout the world, and the global viral conjunctivitis drugs market is anticipated to be hampered as a result. The COVID-19 outbreak has impacted the demand and supply of viral conjunctivitis medicines in three ways: by directly impacting production and demand; by indirectly affecting production and demand; and by indirectly affecting production and consumption; by generating distribution channel disruptions; and by having a financial impact on businesses and financial markets; the supply chain and production of viral conjunctivitis medicines are interrupted in India, China, and the United States as a result of countrywide lockdowns. Countries such as Saudi Arabia, the United Arab Emirates, Egypt, and others, on the other hand, are having difficulty transporting narcotics from one location to another.
Infants may have COVID-19 eye symptoms more frequently than adults, according to a report published in the medical journal JAMA Ophthalmology Journal on June 3, 2020. According to the same source, researchers in Wuhan, China, evaluated 216 children aged 2 to 11 years old, finding that all of them tested positive for COVID-19. Many of the symptomatic individuals had typical coronavirus symptoms including fevers and coughing, and 22.7 percent of the youngsters in the study had ‘different visual signs.’ This demonstrates that the coronavirus has an effect on the patients’ eyes. Furthermore, adult patients with coronavirus infection get pink eye or conjunctivitis, although at a considerably lower prevalence of 1 percent to 3 percent.
Browse 33 Market Data Tables and 25 Figures spread through 214 Pages and in-depth TOC on Global Viral Conjunctivitis Drugs Market, by Drug Class (Antibiotics, Artificial tears, Steroids, NSAIDS, Anti-histamines, Anti-Viral drugs, and Decongestants), by Virus Type (Enterovirus and Adenovirus), by Distribution Channel (Online Pharmacies, Hospital Pharmacies, and Retail Pharmacies), and by Region (North America, Asia Pacific, Latin America, Europe, Middle East, and Africa).
The global viral conjunctivitis drugs market is projected to expand due to the introduction of new treatments for the treatment of viral conjunctivitis. Nicox, an international ophthalmology firm, announced in March 2020 that its U.S. licensee, Eyevance Pharmaceuticals, located in Fort Worth, had released ZERVIATETM in the U.S.
Due to development in prospective markets, particularly in Asia Pacific, the global viral conjunctivitis drugs market is anticipated to increase at a CAGR of 4.7 percent over the forecast period (2021-2028). North America, on the other hand, is anticipated to account for the majority of market shares throughout the projection period (2021-2028) due to an increase in product releases. F
LUMIFY, the first and only over-the-counter (OTC) eye drop created with low-dose brimonidine tartrate for the treatment of eye inflammation, was launched in May 2018 by Bausch & Lomb, a major worldwide eye health business and fully owned subsidiary of Valeant Pharmaceuticals International.
Key companies contributing in the global viral conjunctivitis drugs market are Panoptes Pharma Ges.m.b.H, Bausch Health Companies Inc., NanoViricides Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Okogen Inc., GlaxoSmithKline Plc., Johnson & Johnson, Novartis International AG, Nicox, and NovaBay Pharmaceuticals, Inc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
- CDN Newswire